SNX-2112
Solid Tumor Malignancy
Esanex Inc.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Solid Tumor Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MODERNA COVID-19 VACCINE RNA National Cancer Institute (NCI) | Phase 2 | CCC |
Snx-5422 Mesylate Hsp90 Inhibitor Esanex Inc. | Phase 1 | CC |
xl495 Exelixis | Phase 1 | CC |
Sibp-A18 Shanghai Institute Of Biological Products | Phase 1 | CC |
177lu-nrt6020 Chengdu New Radiomedicine Technology Co. LTD. | Phase 1 | CC |
FAPi-46 Eben Rosenthal | Early Phase 1 | C |
Same molecule, other indications
SNX-2112 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →